NataliaFijalkowski CallawayMDMS
Ophthalmology • Stanford, CARetinal Disease
Clinical Assistant Professor of Ophthalmology, Stanford University Byers Eye Institute; Medical Director at Roche Genentech
Dr. Fijalkowski Callaway is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000
Summary
- Dr. Natalia Fijalkowski Callaway is an ophthalmologist in East Palo Alto, CA and is affiliated with Stanford Health Care. She received her medical degree from Stanford University School of Medicine and has been in practice 6 years. She specializes in retinal disease and is experienced in vitreoretinal disease and comprehensive ophthalmology.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Surgical Retina and Vitreous, 2018 - 2020
University of Miami/Jackson Health System/Bascom Palmer Eye InstituteResidency, Ophthalmology, 2015 - 2018
Stanford University School of MedicineClass of 2014
Ascension Illinois/ResurrectionInternship, Transitional Year
Certifications & Licensure
CA State Medical License 2018 - 2025
IL State Medical License 2014 - 2015
American Board of Ophthalmology Ophthalmology
Publications & Presentations
PubMed
- Macular Atrophy-Related Observations in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial.Glenn J Jaffe, Briana Cameron, Giulio Barteselli, Natalia Callaway, Cindy Skalak
Ophthalmology. Retina. 2025-02-25 - 2 citationsEndophthalmitis in Eyes Treated with the Port Delivery System with Ranibizumab: Summary of Cases during Clinical Trial Development.David A Eichenbaum, William R Freeman, Margaret A Chang, Logan Brooks, Nauman Chaudhry
Ophthalmology. Retina. 2025-02-01 - 1 citationsInterim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration.Peter A Campochiaro, David Eichenbaum, Margaret A Chang, W Lloyd Clark, Jordan M Graff
Ophthalmology. Retina. 2025-02-01
Industry Relationships
- Personalized Healthcare Fellow, Genetech
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
